These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

971 related items for PubMed ID: 10942925

  • 1. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F, Azzaro MP, Palumbo G, Bagnato S, Giustolisi G, Floridia P, Sortino G, Giustolisi R.
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [Abstract] [Full Text] [Related]

  • 2. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H, Wierzbowska A, Robak T.
    Eur Cytokine Netw; 2003 Aug; 14(1):40-51. PubMed ID: 12799213
    [Abstract] [Full Text] [Related]

  • 3. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS.
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [Abstract] [Full Text] [Related]

  • 4. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
    Robak E, Woźniacka A, Sysa-Jedrzejowska A, Stepień H, Robak T.
    Eur Cytokine Netw; 2001 Jan; 12(3):445-52. PubMed ID: 11566625
    [Abstract] [Full Text] [Related]

  • 5. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F.
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [Abstract] [Full Text] [Related]

  • 6. Angiogenic protein expression in advanced epithelial ovarian cancer.
    Barton DP, Cai A, Wendt K, Young M, Gamero A, De Cesare S.
    Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
    [Abstract] [Full Text] [Related]

  • 7. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
    Neben K, Moehler T, Egerer G, Kraemer A, Hillengass J, Benner A, Ho AD, Goldschmidt H.
    Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
    [Abstract] [Full Text] [Related]

  • 8. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF, Standal T, Nielsen JL, Heickendorff L, Borset M, Sørensen FB, Abildgaard N.
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [Abstract] [Full Text] [Related]

  • 9. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    Tabone MD, Landman-Parker J, Arcil B, Coudert MC, Gerota I, Benbunan M, Leverger G, Dosquet C.
    Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
    [Abstract] [Full Text] [Related]

  • 10. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
    Alexandrakis MG, Sfiridaki A, Miyakis S, Pappa C, Kandidaki E, Alegakis A, Margioris AN.
    Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
    [Abstract] [Full Text] [Related]

  • 11. [Coexpression of VEGF and bFGF is associated with increased vascular density in head and neck carcinomas].
    Riedel F, Götte K, Schwalb J, Bergler W, Hörmann K.
    Laryngorhinootologie; 2000 Dec; 79(12):730-5. PubMed ID: 11199455
    [Abstract] [Full Text] [Related]

  • 12. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E, Terpos E, Papaioannou M, Hatjileontis C, Kaloutsi V, Galaktidou G, Gerotziafas G, Christakis J, Zervas K.
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [Abstract] [Full Text] [Related]

  • 13. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
    Nilsson A, Janson ET, Eriksson B, Larsson A.
    Anticancer Res; 2001 Dec; 21(6A):4087-90. PubMed ID: 11911297
    [Abstract] [Full Text] [Related]

  • 14. Angiogenesis in multiple myeloma.
    Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M, Sezer O.
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL.
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [Abstract] [Full Text] [Related]

  • 16. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L, Andrýs C, Krejsek J, Belada DZ, Zák P, Siroký O, Malý J.
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [Abstract] [Full Text] [Related]

  • 17. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
    Tosi P, Zamagni E, Cellini C, Ronconi S, Patriarca F, Ballerini F, Musto P, Di Raimondo F, Ledda A, Lauria F, Masini L, Gobbi M, Vacca A, Ria R, Cangini D, Tura S, Baccarani M, Cavo M.
    Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
    [Abstract] [Full Text] [Related]

  • 18. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
    Salgado R, Vermeulen PB, Benoy I, Weytjens R, Huget P, Van Marck E, Dirix LY.
    Br J Cancer; 1999 May; 80(5-6):892-7. PubMed ID: 10360671
    [Abstract] [Full Text] [Related]

  • 19. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
    Brattström D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, Brodin O, Wagenius G.
    Anticancer Res; 1998 May; 18(2A):1123-7. PubMed ID: 9615776
    [Abstract] [Full Text] [Related]

  • 20. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response.
    Pour L, Svachova H, Adam Z, Almasi M, Buresova L, Buchler T, Kovarova L, Nemec P, Penka M, Vorlicek J, Hajek R.
    Ann Hematol; 2010 Apr; 89(4):385-9. PubMed ID: 19784651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.